PropThink’s Weekly Wrap-Up
Recap - A patent extension for Folotyn added five years to the drug’s market exclusivity and elicited a rally in Spectrum (SPPI) on Monday, but the news … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
NPSP Investors Take Advisory Panel Notes as a Good Sign for Gattex
Long Ideas - The FDA posted notes Friday for its upcoming Advisory Committee meeting, stating that the governing body is in agreement with NPS Pharmaceuticals (NASDAQ:NPSP) on the … Continue Reading
Read nowDiabetes, Carcinoid Syndrome Drive Lexicon’s Late-Stage Pipeline
Long Ideas - Two pertinent announcements from Lexicon Pharmaceuticals (NASDAQ:LXRX) are giving shares a 7% lift on Friday morning. The company reported top-line data from the latest Phase … Continue Reading
Read nowQCOR Strengthening On Positive Clinical Data To Be Presented Soon
Long Ideas - Questcor Pharmaceuticals (NASDAQ:QCOR), to no one’s surprise, remains volatile. Notably, the stock hit an intraday low of $17.60 on October 5th, and closed Thursday 19.5% … Continue Reading
Read nowA Fresh Look At KERX; High Odds For Zerenex Phase III Success
Long Ideas - Keryx Biopharmaceuticals (NASDAQ:KERX) announced disappointing news earlier this year for its cancer compound perifosine, and the stock remains in the penalty box. However, the story … Continue Reading
Read nowNew Leadership Positions Prompt Rally in ROSG
- Shares of Rosetta Genomics (NASDAQ:ROSG) climbed 13% Thursday morning after the company announced the hiring of a Chief Medical Officer and Chief Scientific Officer, both … Continue Reading
Read nowAmicus Moving on Phase II Data, Interest Ahead of Phase III Release in 4Q
Long Ideas - Trading in Amicus Therapeutics (NASDAQ:FOLD) picked up considerably in the last few days, driving the stock up 19% to a high of $6.15 on Tuesday … Continue Reading
Read now